Risk of second cancer after initial treatment of breast cancer: An Osaka Cancer Registry Database study

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 963-973

  Kamigaki, Yumi ^a   Kawakami, Koji ^b  

^a KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Breast cancer; Cancer Registry database; Second cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BILE DUCT CANCER; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; GALLBLADDER CANCER; HORMONAL THERAPY; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; LYMPHOCYTE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; OVARY CANCER; PANCREAS CANCER; PHARYNX CANCER; RECTUM CANCER; RISK ASSESSMENT; SECOND CANCER; SKIN CANCER; SMALL INTESTINE CANCER; STOMACH CANCER; THYROID CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

EID: 79960331335     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.339     Document Type: Article

References (38)

1. Minami Y, Tsubono Y, Nishino Y, Ohuchi N, Shibuya D and Hisamichi S: The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer 108: 901-906, 2004.
2. Tsukuma H, Ajiki W, Ioka A and Oshima A: Research Group of Population-Based Cancer Registries of Japan. Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol 36: 602-607, 2006.
3. Knight JA, Bernstein L, Largent J, et al: WECARE Study Collaborative Group, Bernstein JL. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. Am J Epidemiol 169: 962-968, 2009.
4. Sánchez L, Lana A, Hidalgo A, et al: Risk factors for second primary tumours in breast cancer survivors. Eur J Cancer Prev 17: 406-413, 2008.
5. Travis LB, Andersson M, Gospodarowicz M, et al: Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92: 1165-1171, 2000.
6. Allan JM and Travis LB: Mechanisms of therapy-related carci¬nogenesis. Nat Rev Cancer 12: 943-955, 2005.
7. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340: 351-357, 1999.
8. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998.
9. Swerdlow AJ and Jones ME: Tamoxifen treatment for breast cancer and risk of endometrial cancer, a case-control study. J Natl Cancer Inst 97: 375-384, 2005.
10. Yamazawa K, Miyazawa Y, Suzuki M, Wakabayashi M, Kaku H, Matsui H and Sekiya S: Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer. Surg Today 36: 41-46, 2006.
11. Matsuyama Y, Tominaga T, Nomura Y, et al: Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol 11: 1537-1543, 2000.
12. Travis LB, Hill DA, Dores GM, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290: 465-475, 2003.
13. Dores GM, Metayer C, Curtis RE, et al: Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20: 3484-3494, 2002.
14. Mellemkjaer L, Friis S, Olsen JH, et al: Risk of second cancer among women with breast cancer. Int J Cancer 118: 2285-2292, 2006.
15. Cluze C, Delafosse P, Seigneurin A and Colonna M: Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. Eur J Cancer Prev 18: 343-348, 2009.
16. Kirova YM, de Rycke Y, Gambotti L, Pierga JY, Asselain B and Fourquet A. Institut Curie Breast Cancer Study Group: Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98: 870-874, 2008.
17. Murakami R, Hiyama T, Hanai A and Fujimoto I: Second primary cancers following female breast cancer in Osaka, Japan - a population-based cohort study. Jpn J Clin Oncol 17: 293-302, 1987.
18. Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N and Oshima A: Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res 92: 1-8, 2001.
19. Peters-Engl C, Frank W, Danmayr E, Friedl HP, Leodolter S and Medl M: Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat 54: 255-260, 1999.
20. Van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452, 1994.
21. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL and Cronin WM: Endometrial cancer in tamox¬ifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527-537, 1994.
22. Howard RA, Gilbert ES, Chen BE, et al: Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat 105: 359-368, 2007.
23. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, et al: Acute monocytic or myelomonocytic leukemia with balanced chro¬mosomal translocations to band 11q23 after therapy with 4-epidoxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 10: 1444-1515, 1992.
24. Smith RE: Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project expe¬rience. Clin Breast Cancer 4: 273-279, 2003.
25. Smith RE, Bryant J, DeCillis A and Anderson S: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21: 1195-1204, 2003.
26. Tallman MS, Gray R, Bennett JM, et al: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 13: 1557-1563, 1995.
27. Crump M, Tu D, Shepherd L, Levine M, Bramwell V and Pritchard K: Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21: 3066-3071, 2003.
28. Satyamoorthy K and Perchellet JP: Inhibition of mouse skin tumor promotion by adriamycin and daunomycin in combination with verapamil or palmitoylcarnitine. Cancer Lett 55: 135-142, 1990.
29. Wattenberg LW, Wiedmann TS and Estensen RD: Chemo-prevention of cancer of theupper respiratory tract of the Syrian golden hamster by aerosol administration ofdifluoromethyl-ornithine and 5-fluorouracil. Cancer Res 64: 2347-2349. 2004.
30. Andersson M, Jensen MB, Engholm G and Storm HH: Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncol 47: 755-764. 2008.
31. Schaapveld M, Visser O, Louwman MJ, et al: Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 26: 1239-1246, 2008.
32. Galper S, Gelman R, Recht A, et al: Second nonbreast malig¬nancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 52: 406-414, 2002.
33. Fowble B, Hanlon A, Freedman G, Nicolaou N and Anderson P: Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 51: 679-690, 2001.
34. Rubino C, de Vathaire F, Diallo I, Shamsaldin A and Lê MG: Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 61: 183-195, 2000.
35. Brown LM, Chen BE, Pfeiffer RM, et al: Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 106: 439-451, 2007.
36. Kirova YM, Gambotti L, de Rycke Y, Vilcoq JR, Asselain B and Fourquet A: Risk of second malignancies after adjuvant radio¬therapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys 68: 359-363, 2007.
37. Bernstein JL, Haile RW, Stovall M, et al: WECARE Study Collaborative Group. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst 102: 475-483. 2010.
38. Stovall M, Smith SA, Langholz BM, et al: Dose to the contra¬lateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study. Int J Radiat Oncol Biol Phys 72: 1021-1030, 2008.